- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01656265
Study of ARQ 197 in Hepatocellular Carcinoma (HCC)
February 28, 2017 updated by: Kyowa Kirin Co., Ltd.
Phase I Study of ARQ 197 in Advanced Hepatocellular Carcinoma
The purpose of this study is to evaluate the safety and tolerability of ARQ 197 in hepatocellular carcinoma (HCC) patients treated with daily oral ARQ 197, to determine the recommended dose of ARQ 197 in advanced HCC patients.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Chiba
-
Kashiwa-city, Chiba, Japan
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Confirmed HCC patients who are resistant to, intolerable to, or rejecting a systemic sorafenib therapy
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Child-Pugh classification A at the time of registration
- Adequate bone marrow, liver, and renal functions within 14 days prior to registration
Exclusion Criteria:
- Prior therapy with a c-Met inhibitor (including ARQ 197)
- Any systemic anti-tumor treatment or investigational agent within 2 weeks prior to registration. If the treatment/agent was antibody, within 4 weeks
- Local treatment for malignancy within 4 weeks prior to registration
- Major surgical procedure within 4 weeks prior to registration
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ARQ 197
|
Daily repeating dose of oral ARQ 197, twice a day just after meals.
Dose of ARQ 197 will be escalated according to 3+3 rule.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with dose-limiting toxicity (DLT), as a measure of safety and tolerability
Time Frame: DLT observation period will be the first 28 days after the start of ARQ 197 treatment.
|
Adverse Event collection and assessment will be done for all treated subjects to assess the safety, tolerability.
The grading for the severity of the adverse events will be determined according to CTCAE ver 4.0.
|
DLT observation period will be the first 28 days after the start of ARQ 197 treatment.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Profiles of Pharmacokinetics
Time Frame: Plasma sample correction at pre-dose 1, 2, 4, 6, 10, 12 and 24 hours on day 1; at pre-dose, 1, 2, 4, 6, 10, 12 hours on day 15; and at pre-dose on day 29.
|
maximum concentration (Cmax), area under the curve (AUC), half-life (t1/2), apparent clearance (Cl/F), and apparent volume of distribution in the terminal elimination phase (Vz/F).
|
Plasma sample correction at pre-dose 1, 2, 4, 6, 10, 12 and 24 hours on day 1; at pre-dose, 1, 2, 4, 6, 10, 12 hours on day 15; and at pre-dose on day 29.
|
Antitumor effects according to RECIST 1.1.
Time Frame: Every 6 weeks
|
Every 6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2012
Primary Completion (Actual)
March 1, 2014
Study Completion (Actual)
March 1, 2014
Study Registration Dates
First Submitted
July 20, 2012
First Submitted That Met QC Criteria
July 31, 2012
First Posted (Estimate)
August 2, 2012
Study Record Updates
Last Update Posted (Actual)
March 3, 2017
Last Update Submitted That Met QC Criteria
February 28, 2017
Last Verified
February 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ARQ 197-008
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Hepatocellular Carcinoma
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedAdvanced Adult Hepatocellular Carcinoma | Advanced Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma | BCLC Stage B Adult Hepatocellular Carcinoma | BCLC Stage C Adult Hepatocellular CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingAdvanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | BCLC Stage A Hepatocellular CarcinomaUnited States
-
Jonsson Comprehensive Cancer CenterMerck Sharp & Dohme LLC; Highlight TherapeuticsTerminatedAdvanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Refractory Hepatocellular CarcinomaUnited States
-
Roswell Park Cancer InstituteMerck Sharp & Dohme LLCActive, not recruitingAdvanced Adult Hepatocellular Carcinoma | Child-Pugh Class A | Stage III Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular...United States
-
The University of Hong KongUnknownAdvanced Hepatocellular Carcinoma | Metastatic Hepatocellular CarcinomaChina
-
Mayo ClinicRecruitingAdvanced Hepatocellular Carcinoma | Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8United States
-
AmgenCompletedAdvanced Hepatocellular Carcinoma | Inoperable Hepatocellular Carcinoma
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma | Stage III... and other conditionsUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityWithdrawnUnresectable Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Locally Advanced Hepatocellular Carcinoma
-
University of WashingtonExelixisTerminatedAdvanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular CarcinomaUnited States
Clinical Trials on ARQ 197
-
National Cancer Institute (NCI)TerminatedEpithelioid Mesothelioma | Sarcomatoid Mesothelioma | Stage IV Pleural Mesothelioma | Recurrent Malignant Mesothelioma | Stage II Pleural Mesothelioma | Stage III Pleural MesotheliomaUnited States
-
National Cancer Institute (NCI)CompletedChildhood Solid NeoplasmUnited States, Canada
-
ArQule, Inc. (a wholly owned subsidiary of Merck...CompletedRenal Cell Carcinoma (RCC) | Alveolar Soft Part Sarcoma (ASPS) | Clear Cell Sarcoma (CCS)United States, Canada, United Kingdom
-
ArQule, Inc. (a wholly owned subsidiary of Merck...Completed
-
National Cancer Institute (NCI)CompletedStage IV Breast Cancer | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedProstate Adenocarcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate CancerUnited States
-
Kyowa Kirin Co., Ltd.Completed
-
ArQule, Inc. (a wholly owned subsidiary of Merck...CompletedCancer, Advanced Solid TumorsUnited Kingdom
-
Daiichi Sankyo, Inc.ICON Clinical Research; ArQule, Inc. (a wholly owned subsidiary of Merck Sharp...Completed
-
ArQule, Inc. (a wholly owned subsidiary of Merck...Completed